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ABSTRACT
Background: CT-P13, the first biosimilar monoclonal antibody to infliximab (IFX), has been confirmed to
be efficacious in inducing remission in inflammatory bowel diseases (IBD). The aim of this study was to
evaluate the long-term efficacy and safety of CT-P13 therapy in Crohn’s disease (CD) and ulcerative
colitis (UC), and to identify predictors of sustained clinical response during a 54-week CT-P13 treatment
period.
Patients and methods: Patients with CD and UC, who were administered CT-P13, were prospectively
enrolled. Clinical response was assessed at week 14 and week 54. Predictive factors for disease outcome
at week 54 were evaluated.
Results: 57 CD and 57 UC patients were included; 55 CD and 49 UC patients completed the induction
therapy and 50 CD and 46 UC patients completed the 54-week treatment period. Clinical remission was
achieved in 65.5% of CD and 75.5% of UC patients at week 14. Rate of continuous clinical response was
51% in both CD and UC at week 54. None of the examined parameters were predictive to the clinical
outcome neither in CD, nor in UC.
Conclusion: This study confirmed the long-term efficacy and safety of CT-P13 therapy in IBD. Response
rates at week 54 were similar in CD and UC.
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1. Introduction
CT-P13, a biosimilar of infliximab (IFX), was the first monoclo-
nal antibody biosimilar approved by the European Medicines
Agency. Following the two pivotal clinical trials that confirmed
the efficacy of CT-P13 in patients with rheumatoid arthritis and
ankylosing spondylitis [1,2], data became available on short-
term response to CT-P13 in inflammatory bowel diseases
(IBDs). However, considering the number of full articles pub-
lished in this topic, experience with the biosimilar IFX, mainly
with long-term use, is still limited. We have already published
an 8-week data of the efficacy of CT-P13 IFX biosimilar in
Crohn’s disease (CD) and ulcerative colitis (UC), and the multi-
center Hungarian study has also confirmed the effectiveness
and safety of CT-P13 therapy in the induction of clinical
response and remission on large number of IBD patients
very soon afterwards [3,4].
The ACCENT and ACT trials were the landmark randomized
controlled trials demonstrating clearly that the originator IFX
can maintain remission after inducing response in both dis-
eases [5,6]. Considering the initial data on the similar short-
and mid-term efficacy of the biosimilar product, it is entitled to
suppose that long-term efficacy may also be comparable to
the reference drug. However, confirmation data are still miss-
ing in the field of IBD. It should also not be forgotten that
initially several national societies have raised concerns regard-
ing the use of biosimilars in extrapolated indications [7].
Therefore, data from clinical studies on the comparable effi-
cacy are extremely important and required both in induction
and maintenance therapy, even if the cost-effectiveness of the
biosimilar drug compared to the originator one is well known.
The aim of the present study was to evaluate the long-term
clinical efficacy and safety of CT-P13 therapy in CD and UC and
to identify the predictive factors of loss of response (LOR) in
this study population.
2. Patients and methods
2.1. Study design and patients
This was a prospective observational study conducted
between June 2014 and September 2016 at the 1st
Department of Medicine, University of Szeged. Patients
18 years of age and older diagnosed with CD and UC, who
were administered CT-P13, were enrolled. Eligible Crohn’s
patients had moderate-to-severe therapy-refractory or ster-
oid-dependent luminal disease or therapy-refractory simple
fistulizing disease or complex fistulas. Patients with UC had
therapy-refractory, steroid-dependent, or moderate-to-severe
acute steroid-refractory colitis. Clinical outcome was
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estimated at fixed appointments throughout the 54-week
treatment period. Medical records analyzed included
patients’ demographic and clinical characteristics, presence
of extraintestinal manifestations, previous surgeries, smoking
and family history, previous history of originator IFX admin-
istration, concomitant medications, response to CT-P13, and
adverse drug reactions. According to the national regulation,
none of the patients received IFX treatment with the origi-
nator compound within 12 months before initiation of the
biosimilar IFX.
2.2. Assessments of response to CT-P13 and end points
CT-P13 5 mg/kg was given as an intravenous infusion at
weeks 0, 2, and 6 followed by a maintenance regimen of
5 mg/kg every 8 weeks. Clinical disease activity was
assessed by the Crohn’s Disease Activity Index (CDAI) [8]
and the partial Mayo (pMayo) Scoring System in UC [9] at
weeks 0, 2, 6, 14, 22, 30, 46, and 54. Continuous clinical
response (CCR) was defined as a maintained response
through week 54 without intermediate relapse. CD response
was defined as a >100-point decrease in CDAI. UC response
was defined as >30% decrease in the activity index and a
decrease in rectal bleeding and endoscopy subscores.
Remission was defined as CDAI below 150 for luminal CD,
and for UC, it was defined as a pMayo score ≤2, with no
individual subscores >1. The severity of perianal CD was
evaluated by Perianal Disease Activity Index (PDAI) [10].
Clinical response was defined by a decrease of 50% or
more in the number or amount of fistula discharge, and
clinical remission was defined as a complete closure of
fistulas. Fistula closure was defined as no drainage, either
spontaneous or with gentle compression. Primary nonre-
sponse was defined as a failure to achieve clinical response
following the induction phase of CT-P13. LOR was defined
as an increase in CDAI of at least 70 points in CD and an
increase in the pMayo score of 2 or more with an absolute
pMayo score of 4 or higher. The primary end points were
CCR and clinical remission during the 54-week therapeutic
period. The secondary end points were clinical and bio-
chemical responses and safety evaluated at weeks 14 and
54. A further secondary end point was the identification of
predictors of sustained clinical response during 54-week CT-
P13 treatment period.
2.3 Assessment of laboratory parameters, serum drug
and antibody levels, and fecal calprotectin
concentrations
CT-P13 trough levels and antibody titers (ATI) as well as
C-reactive protein (CRP) level, leukocyte, hematocrit, plate-
let count, and serum albumin were determined at every
visit. Fecal calprotectin was measured by using lateral flow
assay at weeks 2, 6, and 46. Enzyme-linked immunosorbent
assay was applied to determine CT-P13 trough levels and
ATI (LISA TRACKER, Theradiag, France). Cutoff value for CRP
was 5 mg/l, and for fecal calprotectin, it was 300 µg/g. The
detection cutoff value of CT-P13 trough level was 0.1 μg/
ml, while 3–7 μg/ml was defined as therapeutic. The
standard cutoff value of ATI level was 10 ng/ml. ATI posi-
tivity was defined above the cutoff value of ATI level.
2.4. Statistical analysis
Continuous variables are presented as mean ± standard devia-
tion and are compared among groups with Mann–Whitney
U-test; categorical variables are presented as frequency (percen-
tage) and are compared among groups with Fisher’s exact test.
The examined variables in CD were CT-P13 trough levels at
weeks 2, 6, and 14; antibody positivity at weeks 2, 6, and 14;
CRP level at baseline and at weeks 2, 6, 14, 30, and 46; fecal
calprotectin at weeks 2, 6, and 46; concomitant steroid and
azathioprine therapy at the time of induction therapy and at
week 30; previous use of antitumor necrosis factor (TNF) drug;
and need of dose intensification. In UC, examined variables
consisted of CT-P13 trough levels at weeks 2, 6, 14, 30, and 46;
antibody positivity at weeks 2, 6, 14, 30, and 46; CRP level at
baseline and at weeks 2, 6, 14, 30, and 46; fecal calprotectin at
weeks 2, 6, and 46; concomitant steroid and azathioprine ther-
apy at the time of induction therapy and at week 30; previous
use of anti-TNF drug; and need of dose intensification.
Confidence intervals (CIs) for proportions were calculated
with the Clopper–Pearson method. The changes from baseline
in continuous variables (e.g. CRP, fecal calprotectin, CDAI, and
pMayo score) were compared using paired-samples t-tests.
For the multivariate modeling of response, logistic regres-
sion was used with L2-penalization selected with Tsai’s cor-
rected AIC [11]. Results are visualized as odds ratios on log
scale with 90%, 95%, and 99% CIs (using different shading).
The significance was set at p < 0.05.
2.5. Ethical approval
Ethical approval was acquired from the National Ethical
Committee 929772–2/2014/EKU [292/2014]).
3. Results
3.1. Patient population and disease activities
Fifty-seven CD and the same number of UC patients were
included of which 55 CD and 49 UC patients completed the
induction therapy and 50 CD and 46 UC patients completed
the 54-week treatment period. In CD, the indication of CT-P13
therapy was luminal disease in 38, fistulizing disease in 12
cases, and both luminal and fistulizing diseases in 7 cases. In
UC, therapy was started due to either acute onset or severe
flare-up in 32 and chronic refractory activity in 25 patients.
Previous anti-TNF therapy was administered for seven CD
(three originator IFX and four adalimumab) and nine UC (six
originator IFX, two adalimumab, and one golimumab)
patients. In CD, previous anti-TNF therapy resulted in remis-
sion in two cases and in UC in six patients. Demographic data
and clinical characteristics of all of the enrolled patients and
those who completed week 54 are detailed in Tables 1 and 2.
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3.2. Response to CT-P13 therapy
3.2.1. Response to the induction phase, primary
nonresponse
Of the 55 CD patients who completed induction therapy,
clinical response was achieved in 53 patients (96.4%) (95%
CI, 87.5–99.6] – remission in 36 and partial response in 17
patients. Two patients showed primary nonresponse at week
14; their therapy was stopped. In UC, 49 patients completed
induction therapy. Clinical response was achieved in 48
patients (97.9%) (95% CI, 89.1–99.9) at week 14 – remission
in 37 and partial response in 11 patients. Three patients
underwent colectomy before week 14: two of them because
of nonresponse to the therapy and one because of the diag-
nosis of colonic dysplasia. At week 14, colectomy was required
in one further patient due to nonresponse.
3.2.2. CCR during the maintenance phase, LOR
CCR was shown in 28 (50.9%) (95% CI, 22.2–48.6) CD patients
at week 54. Of the 50 patients who completed week 54, 31
patients (62%) (95% CI, 48.6–80.4) were in clinical remission, 9
showed partial response, and 10 at active disease at week 54
(20%) (95% CI, 9.6–37.3). Twenty-three patients showed LOR
between weeks 14 and 54. The overall rate of primary non-
response and LOR during the therapy was 43.9% (95% CI,
26.0–52.4). Steroid was administered in four, dose escalation
Table 1. Demographic data and clinical characteristics of the patients enrolled in
the study.
CD patients
(n = 57)
UC patients
(n = 57)
Mean age at diagnosis (years) 28 (10–55) 31 (15–65)
Mean disease duration (years) 9 (0–27) 7 (0–22)
Male/female ratio 31/26 29/28
Smoking history
● – Ex-smoker 5 5
● – Current smoker 13 1
● – Never smoked 26 19
● – No data 3 8
Family history for IBD 2 2
Surgical history
● – Bowel resection 17 0
● – Fistula/abscess surgery
● Colectomy
18
1
0
1
Location/extent
● – Ileal 7 0
● – Colonic 16 0
● – Ileocolonic 26 0
● – Upper GI 1 0
● – Ileocolonic + upper GI 7 0
● – Extensive colitis 0 27
● – Left-sided colitis 0 25
● – Proctitis 0 5
Behavior
● – Inflammatory 19 0
● – Stenotizing 17 0
● – Penetrating 21 0
Extraintestinal manifestation
● – Arthralgia/arthritis 14 15
● – Erythema nodosum/
pyoderma
8 3
– gangrenosum
– Scleritis/episcleritis/uveitis
0 2
Previous medications
– 5-Aminosalycilates
– Corticosteroids
– Thiopurines
36
43
51
48
48
42
– Cyclosporine
0 6
– Anti-TNF-α
7 9
Efficacy of previous anti-TNF-α
therapy
● – Remission 2 6
● – Response 0 0
● – No response/loss of response 5 2
● – Allergy 0 1
Concomitant medications at
induction
● – 5-Aminosalycilate 17 37
● – Corticosteroids 21 35
● – Thiopurines 34 26
UC: ulcerative colitis; CD: Crohn’s disease; TNF: tumor necrosis factor; IBD:
inflammatory bowel disease; GI: Gastrointestinal tract.
Table 2. Demographic data and clinical characteristics of the patients com-
pleted week 54.
CD patients
(n = 50)
UC patients
(n = 46)
Mean age at diagnosis (years) 28 (10–55) 30.5 (17–65)
Mean disease duration (years) 9 (0–27) 8 (0–22)
Male/female ratio 27/23 24/22
Smoking history
● – Ex-smoker 5 8
● – Current smoker 13 1
● – Never smoked 30 30
● – No data 2 7
Family history for IBD 2 4
Surgical history
● – Bowel resection 15 0
● – Fistula/abscess surgery 16 0
● – Colectomy 1 1
Location/extent
● – Ileal 6 0
● – Colonic 14 0
● – Ileocolonic 23 0
● – Upper GI 1 0
● – Ileocolonic + upper GI 6 0
● – Extensive colitis 0 21
● – Left-sided colitis 0 22
● – Proctitis 0 3
Behavior
● – Inflammatory 17 0
● – Stenotizing
● Penetrating
15
18
0
0
Extraintestinal manifestation
● – Arthralgia/arthritis 10 11
● – Erythema nodosum/
pyoderma
6 2
● – gangrenosum 1 1
● – Scleritis/episcleritis/uveitis
Previous medications
● – 5-Aminosalycilates 29 40
● – Corticosteroids 37 41
● – Thiopurines 44 35
● – Cyclosporine 0 6
● – Anti-TNF-α 5 7
Efficacy of previous anti-TNF-α
therapy
● – Remission 1 4
● – Response 0 0
● – No response/loss of response 4 2
● – Allergy 0 1
Concomitant medications at
induction
● – 5-Aminosalycilate 16 29
● – Corticosteroids 18 29
● – Thiopurines 30 22
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was used in six, and combined steroid therapy and dose
escalation was given in four patients with LOR. Five patients
required surgical intervention, two of them underwent ileoce-
cal resection, one patient underwent right hemicolectomy,
and two needed perianal abscess surgery. CT-P13 therapy
was continued in three of the operated patients after the
surgery. No intervention was applied in three cases with
LOR. Considering patients who required CT-P13 therapy
because of perianal fistulas and completed week 54, partial
response was achieved in five patients and remission with
complete closure of all of the fistulas was achieved in four
patients. Three patients showed LOR with continuous fistula
discharge. At week 54, 15 patients stopped CT-P13 therapy
based on the decision of the physician.
In UC, CCR was detected in 25 (51%) (95% CI, 23.4–51.7)
patients at week 54. Of the 46 patients who completed the 54-
week treatment period, 30 patients (65.2%) (95% CI, 40.6–76.3)
were in remission, nine patients showed partial response, and
seven patients at active disease (15.2%) (95% CI, 7.2–36.4) at
week 54. LOR occurred in 22 patients after the induction
therapy. Steroid was given in five, dose escalation was used
in seven, and steroid and dose escalation was combined in six
patients. No intervention was applied in four patients. One of
the patients did not respond to dose escalation and had to be
operated on before achieving week 54. The overall rate of
primary nonresponse and LOR was 40.4% (95% CI, 20.8–47.9)
at week 54. At week 54, the gastroenterologist decided to stop
CT-P13 therapy for 24 patients.
In both diseases, CT-P13 therapy was stopped only in case
of remission or CCR. Therapy discontinuation has always been
discussed with the patients since in some cases with the same
outcome therapy was continued because of the patients’ pre-
vious complicated disease course, surgeries, responses to
other treatments, need of dose escalation, etc. Figure 1
shows a flowchart with the number of patients enrolled in
the study and completed induction and 54-week therapy.
3.3. Changes in activity scores and laboratory
parameters
In CD, mean CDAI was 305.27 ± 11.2 and mean PDAI was
7.83 ± 0.6 at the beginning of CT-P13 therapy.
Determination of fecal calprotectin was available in 18 CD
and 17 UC patients. In CD, mean CDAI scores at weeks 14
and 54 decreased from the baseline value of 307 ± 20.1 to
106.3 ± 14.5 and 118 ± 19.8 (p < 0.001 in both cases). Mean
PDAI scores at weeks 14 and 54 decreased from the baseline
value of 10 ± 0.58 to 2.4 ± 1.3 and 3.3 ± 0.9 (p = 0.001 and
p = 0.003). However, mean value of CDAI and PDAI scores did
not change significantly in patients who completed the 54-
week treatment period compared to the mean values of their
CDAI and PDAI scores at week 14 (p = 0.38 and p = 0.29). CRP
levels dropped significantly in weeks 14 and 54 compared to
the baseline values (27.7 ± 6.9 to 9.86 ± 2.8, p = 0.01, and to
13.7 ± 4.3, p = 0.05). Mean level of fecal calprotectin did not
decrease significantly at week 54 (725.5–762.3 µg/g, p = 0.38).
In UC, mean pMayo scores at weeks 14 and 54 decreased
significantly from the baseline value of 7.57 ± 0.2 to 2.33 ± 0.5
and 1.15 ± 0.39 (p < 0.001 in both cases). Decrease of the
mean value of pMayo scores from week 14 to week 54 showed
borderline significance (p = 0.055). CRP levels also dropped
significantly in week 14 but not in week 54 compared to the
baseline values (23.5 ± 7.4 to 10 ± 3.3, p = 0.05, and to
9.5 ± 5.9, p = 0.07). Mean level of fecal calprotectin decreased
significantly from the baseline to week 54 (953.4–604.5 µg/g,
p ≤ 0.001). Serum CT-P13 levels measured at weeks 14 and 54
did not differ significantly between patients with CCR and
secondary nonresponders neither in CD (7.34 ± 5.93 vs.
4.85 ± 5.05 μg/ml, p = 0.2, and 7.85 ± 9.2 vs. 4.02 ± 5.56 μg/
ml, p = 0.19) nor in UC (6.1 ± 5.4 vs. 5.87 ± 4.58 μg/ml,
p = 0.98, and 4.67 ± 4.59 vs. 4.9 ± 6.1 μg/ml, p = 0.74).
Tables 3 and 4 summarize the laboratory parameters through-
out the treatment period in CD and UC.
3.4. Predictors of outcome
According to univariate analysis, none of the examined para-
meters predicted LOR either in CD or in UC. Moreover, multi-
variate analysis with CRP level and CT-P13 trough level at
week 14, earlier anti-TNF use, baseline steroid requirement,
and dose intensification did not identify any of the variables as
predictors for outcome in CD (Figure 2). In UC, CRP level, CT-
P13 trough level and fecal calprotectin concentration at week
6, baseline steroid requirement, and dose intensification did
Figure 1. (a) Flow chart of CD patients enrolled in the study and completed
induction and 54-week therapy. CD: Crohn’s Disease, CCR: continuous clinical
response, LOR: loss of response. (b). Flow chart of UC patients enrolled in the
study and completed induction and 54-week therapy. UC: ulcerative colitis, CCR:
continuous clinical response, LOR: loss of response.
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not predict the disease outcome (Figure 3). No difference was
observed regarding the clinical outcome at week 54 between
anti-TNF-naive patients and patients previously treated with
an anti-TNF agent.
3.5. Adverse events
In CD, two patients stopped CT-P13 therapy before the
third infusion because of the occurrence of infusion reac-
tion. One patient developed infusion reaction after the
fourth infusion leading to therapy discontinuation. Mild
infusion reaction occurred in three further patients during
the 54-week period; however, CT-P13 therapy did not have
to be discontinued because of this event. In UC, four
patients discontinued CT-P13 therapy before week 14
because of developing infusion reaction. One patient on
combo therapy died after the second infusion: the
azathioprine-induced rapid and severe myelosuppression
and fulminant colitis required colectomy; however, after
the successful surgical intervention, fatal fungal and bac-
terial sepsis with neutropenia occurred. One additional
patient had to stop therapy because of infusion reaction
occurring after the induction phase. Infusion reaction
occurred in four further UC patients after the induction
phase; however, CT-P13 therapy had to be discontinued
in only one of them because of the reaction.
Table 3. Summary of the laboratory parameters throughout the treatment period in Crohn’s disease.
Antitumor necrosis factor drug level (μg/ml) C-reactive protein (mg/l) WBC (g/l) HTC (%) PLT (g/l) ALB (g/l)
Median IQR Median IQR Median IQR Median IQR Median IQR Median IQR
Week 0 0.00 0.00 10.6 31.2 7.6 3.0 310.0 134.0 40.0 9.0 44.0 7.0
Week 2 17.22 14.87 3.9 4.0 6.9 2.8 39.0 7.0 288.0 92.3 45.0 6.0
Week 6 8.904 17.23 3.55 5.4 6.1 2.4 40.0 7.0 276.0 67.0 44.0 5.0
Week 14 6.09 9.85 4.2 5.7 6.8 2.9 40.0 7.0 286.0 75.0 46.0 5.0
Week 30 2.39 6.99 6.4 10.4 6.2 2.6 40.0 6.0 256.0 133.0 45.0 5.0
Week 46 3.03 8.19 5.4 10.4 6.1 2.8 39.5 5.0 261.5 90.8 44.5 5.3
Table 4. Summary of the laboratory parameters throughout the treatment period in ulcerative colitis.
Antitumor necrosis factor drug level (μg/ml) C-reactive protein (mg/l) WBC (g/l) HTC (%) PLT (g/l) ALB (g/l)
Median IQR Median IQR Median IQR Median IQR Median IQR Median IQR
Week 0 0.0 0.0 14.0 35.0 9.5 5.0 37.0 10.3 343.5 153.8 44.0 6.5
Week 2 16.5 11.3 4.9 7.4 8.0 3.7 338.0 161.0 38.0 9.0 44.0 4.0
Week 6 12.2 15.5 3.8 3.6 7.7 3.7 37.0 10.0 292.0 156.0 46.0 5.5
Week 14 5.1 5.9 3.4 4.4 7.7 5.4 39.0 8.0 317.0 144.0 46.0 5.5
Week 30 5.5 7.4 3.0 3.8 6.1 3.1 39.0 7.0 282.0 98.0 48.0 7.0
Week 46 3.2 8.9 2.7 2.2 5.9 2.7 39.0 7.0 255.0 94.0 46.0 4.5
Figure 2. Multivariate analysis of patients to identify predictive factors for
disease outcome in CD. Analyses included the following variables: CRP level
and CT-P13 trough levels at week 14, previous anti-TNF use, dose intensification,
corticosteroid use at baseline. CRP: C-reactive protein.
Figure 3. Multivariate analysis of patients to identify predictive factors for
disease outcome in UC. Analyses included the following variables: CRP level,
CT-P13 trough level and fecal calprotectin concentration at week 6, dose
intensification, corticosteroid use at baseline. CRP: C-reactive protein.
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4. Discussion
The results of this prospective observational study from our
tertiary IBD center revealed CCR in 51% of CD and UC patients
at week 54. Primary and secondary nonresponse occurred in
about 40% of the patients. Therapy had to be discontinued as
a consequence of infusion reaction in 5.3% and 7.2% of the
patients. None of the examined variables proved to be pre-
dictive for long-term disease outcome in either diseases.
Widespread use of biologics has placed substantial financial
burden on health-care systems all over the word. Because of
the high cost of originator anti-TNF agents, interest has grown
in biosimilars that are cost-effective and may sufficiently sup-
ply the reference product. CT-P13 was approved for the same
indications as originator IFX. After the initial concerns about
the extrapolation of clinical data from rheumatic indications to
IBD, some paper has published on the efficacy and safety of
CT-P13 in IBD patients. The increasing data on the comparable
efficacy and safety profile may further decrease the fear of
using biosimilar IFX routinely [3,12–14].
To date, most of the studies have focused on the induction
phase of the therapy, and the published data regarding the
efficacy and safety of long-term CT-P13 use are limited
(Table 5). However, two randomized clinical trials are con-
ducted to evaluate the safety and efficacy of CT-P13 and to
demonstrate its noninferiority on long term [19,20]. Long-term
data became available from a Korean study by Jung et al. [15].
Clinical response rates proved to be high, 87.5% and 100% at
week 54 in anti-TNF-naive CD and UC patients representing a
very favorable efficacy of CT-P13. However, if we consider
responders as the number of patients who completed the
induction phase of the therapy, rates of responders decrease
to 21.8% of CD and 31.6% of UC. Moreover, we should be
cautious when interpreting the data; the retrospective type of
the study design and the small number of patients achieving
week 54 provide only limited information on long-term effi-
cacy of CT-P13. Therefore, further studies are necessary to
evaluate the effect of long-term CT-P13 treatment. The
recently published prospective, multicenter, cohort study by
Fiorino et al. revealed that the whole efﬁcacy in terms of
induction and/or maintenance of remission/response of IFX
biosimilar was high with an estimated efﬁcacy of approxi-
mately 90% at 24 weeks [21]. In our study, response rates at
weeks 14 and 54 proved to be relatively high. However,
response rates are generally better in the real life compared
to clinical trials, and we also should take into consideration
that 36.8% and 60% of our CD patients received concomitant
corticosteroid and/or immunomodulator therapy at inclusion.
In UC, 61.4% and 45.6% of the patients received baseline
corticosteroid and immunomodulator therapy. Both may
improve therapeutic outcome at least on the short term.
Notably, in the PROSIT-BIO cohort, the overall probability of
response rate at week 8 was similarly high, 96.1% respec-
tively [21].
The approval of CT-P13 for the treatment of IBD was based
on the results of trials conducted in rheumatoid arthritis and
ankylosing spondylitis. In the PLANETRA and PLANETAS stu-
dies, CT-P13 demonstrated equivalent efficacy and safety pro-
file to innovator IFX at week 30, but did not provide efficacy
data on long-term [1,2].
Our study prospectively reported data on the long-term
outcome of CT-P13 therapy in IBD. Our results showed higher
response rates in both CD and UC assessed at week 54 com-
pared to the large randomized controlled trials of IFX, the
ACCENT-1 (39%) and the ACT-1 trials (46%) [5,6].
Factors predicting to worse outcome have high clinical
importance. A nationwide prospective and observational
cohort study in Hungary in 210 consecutively recruited
patients with CD or UC revealed that 67.2% of week 14
responder CD and 80% of week 14 responder UC patients
maintained clinical response to CT-P13 at week 30 [4]. The
authors demonstrated that induction treatment with the bio-
similar IFX was less effective in patients previously exposed to
the originator compound. Data on predictors on long-term are
missing. However, the study by Gonczi et al. revealed that
week 2 trough levels of CT-P13 were predictive for short-
Table 5. Summary of the studies examining the efficacy of infliximab biosimilar CT-P13 in IBD.
Study Number of enrolled patients
Outcome at weeks 8–14 Outcome at week 30 Outcome at week 54
Response
rates
Remission
rates
Response
rates
Remission
rates
Response
rates
Remission
rates
Kang et al. [13] 8 CD, 9 UC (n = 17) ND CD: 25%
UC: 56%
ND ND ND ND
Jung et al. [15] 74 CD, 38 UC (n = 112) CD: 90.6%
UC: 81%
CD: 84.4%
UC: 38.1%
CD: 95.5%
UC: 91.3%
CD: 77.3%
UC: 47.8%
CD: 87.5%
UC: 100%
CD: 75%
UC: 50%
Park et al. [16] 95 CD, 78 UC (n = 173) CD: 84.2%
UC: 75.5%
CD: 64.2%
UC: 49.1%
CD: 77.8%
UC: 72.2%
CD: 57.8%
UC: 37%
ND ND
Farkas et al. [3] 18 CD, 21 UC (n = 39) CD: 37.5%
UC: 20%
CD: 50%
UC: 66.7%
ND ND ND ND
Gecse et al. [4] 126 CD, 84 UC (n = 210) CD: 81%
UC: 78%
CD: 54%
UC: 59%
CD: 67%
UC: 80%
CD: 53%
UC: 68%
ND ND
Keil et al. [14] 30 CD, 22 UC (n = 52) CD: 50%
UC: 54.5%
CD: 50%
UC: 40.9%
ND ND ND ND
Jahnsen et al. [12] 46 CD, 32 UC (n = 78) ND CD: 79%
UC: 56%
ND ND ND ND
Smits et al. [17] 57 CD, 24 UC, 2 IBD nonclassified (n = 83) ND CD: 67%
UC: 62%
(16 weeks)
ND ND ND 64%
Kolar et al. [18] 90 CD, 29 UC (119) anti-TNF naive CD: 63.3%
UC: 55.2%
CD: 28.9%
UC: 27.6%
ND ND CD: 37.5%
UC: 24%
(week 46)
CD: 48.6%
UC: 40%
(week 46)
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and medium-term clinical efficacy in UC and were associated
only with short-term clinical outcomes in CD [22]. In our study,
we were not able to show any of the examined parameters to
predict the outcome of CT-P13 therapy at week 54 neither in
CD nor in UC. Fecal calprotectin concentration decreased sig-
nificantly during the 54-week treatment period in UC. Neither
could our study confirm whether previous anti-TNF exposure
is associated with lower response rates. The lower value of the
area under the Receiver Operating Characteristic (ROC) curve,
the higher the false positive or false negative rates may occur.
Thus, diagnostic cut-off value is not worth using in this case.
However, in case of larger sample size, useful ut-off value may
be reached. The relatively low number of patients treated with
anti-TNF previously may result in low statistical power to
reveal significant difference between the two groups.
At week 54, response rates proved to be 75.5% and 81.3%
in week 14 responder CD and UC patients. According to the
Hungarian multicenter study, response and remission rates at
week 54 varied as 58% and 47% in CD and 64% and 53% in UC
[4]. Frequency of infusion reactions was 10.5% in CD and
12.3% in UC patients, which seems to be higher compared
to the existing data, although except for two, all of the
patients were anti-TNF naive.
As a limitation of the study, many characteristics were
compared among the CCR and LOR groups, and the reported
p-values are not corrected for multiplicity. Therefore, these
results should be used cautiously in the light of the multiple
comparisons situation.
Biosimilars were introduced in the EU market in early
2015, and growing data supported the efficacy and safety
of CT-P13 in IBD patients. However, except for the study of
Jung et al., none of the published papers examined the
therapeutic efficacy of IFX biosimilar on long term [15]. It is
well known that acceptance of biosimilars in the medical
community encountered some resistance. This was especially
true for therapeutic indications for which no specific clinical
trials with the biosimilar have been performed and that have
been approved based on extrapolation. The first position
statement of European Crohn's and Colitis Organisation
(ECCO) on the use of biosimilars in the treatment of IBD
was published in 2013 and raised some caution on the use
of biosimilars [23]. ECCO called for more data on the safety
and benefit of biosimilars and recommended rigorous testing
in patients with IBD to ensure that appropriate efficacy and
safety standards are met. ECCO also recommended making
final decisions about the use of biosimilars on an individual
basis. The updated ECCO position statement showed a sig-
nificant shift in attitude from the previous ECCO position
paper [24]. The consensus agreed on, among others, that
switching from the originator to a biosimilar in patients
with IBD is acceptable, and adverse events and LOR cannot
be expected to be overcome with a biosimilar of the same
molecule.
Moreover, while biologics have positively impacted patient
treatment, their high costs may limit patient access to these
medicines. The more the data we have on the efficacy on long
term, the more encouraging the use of biosimilars will be.
Important studies have been recently published including
NOR-SWITCH and PROSIT-BIO – but week 54 data are still
missing [18,25]. We believe that our study has significant addi-
tional information on long-term use of IFX biosimilars in these
indications. Moreover, as strengths of the present work, data on
CT-P13 levels and fecal calprotectin were also available.
Anti-TNF therapies have greatly improved outcomes in IBD,
although they are not universally effective in all patients. A
considerable proportion of initial responders lose response
over time while others may become intolerant to these
agents; therefore, there is a definite need for new therapies.
However, we have long-term experience with anti-TNF agents,
and an appropriate patient selection for the therapy may
increase the number of responders. Moreover, early use of
anti-TNF agents may change the natural course of the disease.
Direct comparisons of different biologicals in IBD would help
in assessing their relative efficacy, and these head-to-head
studies are now in pipeline.
5. Conclusion
To the best of our knowledge, this is the first prospective study
that evaluated and confirmed long-term efficacy and safety of
CT-P13 therapy in IBD. Results of the randomized trials running
presently may serve important data to confirm the expected
safety and long-term efficacy of CT-P13, which has a significant
role in supporting the use of this biosimilar drug in IBD. The
wider use and the clinical benefit may ensure more patients
receive effective therapy in time.
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